The designation is based on results from the EMPEROR-Preserved phase III trial, which established Jardiance as the first therapy to show statistically significant improvement in heart failure outcomes in adults with heart failure with a preserved ejection fraction
Invega Hafyera offers patients the fewest doses per year. Phase 3 non-inferiority study results showed over 92% of participants were relapse-free at 12 months
The lab has been developed to aid surgeons to overcome the challenging learning curve to obtain laparoscopic expertise
New treatment options are critical, as approximately half of all people with heart failure die within five years of diagnosis. Heart failure accounts for more than one million hospitalisations a year in the US
The data suggest that a booster dose given within 6 to 12 months after the second dose may help maintain a high level of protection against COVID-19.
A treatment to prevent extreme symptoms and cut hospitalisation
WHO prequalification enables the procurement of ROTAVAC 5D by UN agencies namely UNICEF and PAHO
ADG20, a novel monoclonal antibody targeting the spike protein of SARS-CoV-2 and related coronaviruses
Cocktails of 2 mAbs based products are better equipped to deal with variants than single mAb based products which have a tendency of losing their efficacy with rapidly generating variants
The vaccine was 85 percent effective in preventing severe disease across all regions.
Subscribe To Our Newsletter & Stay Updated
